Lipocine Inc (LPCN)
5.35
+0.11
(+2.10%)
USD |
NASDAQ |
May 10, 16:00
5.35
0.00 (0.00%)
After-Hours: 19:06
Lipocine Enterprise Value: 5.819M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 5.819M |
| May 08, 2024 | 3.746M |
| May 07, 2024 | 4.597M |
| May 06, 2024 | 4.118M |
| May 03, 2024 | 2.842M |
| May 02, 2024 | 2.949M |
| May 01, 2024 | 3.002M |
| April 30, 2024 | 2.524M |
| April 29, 2024 | 3.108M |
| April 26, 2024 | 3.468M |
| April 25, 2024 | 2.151M |
| April 24, 2024 | 1.567M |
| April 23, 2024 | 3.480M |
| April 22, 2024 | 4.916M |
| April 19, 2024 | 5.979M |
| April 18, 2024 | 6.882M |
| April 17, 2024 | 6.244M |
| April 16, 2024 | 3.268M |
| April 15, 2024 | 6.431M |
| April 12, 2024 | 8.849M |
| April 11, 2024 | 12.04M |
| April 10, 2024 | 12.57M |
| April 09, 2024 | 8.637M |
| April 08, 2024 | 5.926M |
| April 05, 2024 | 3.480M |
| Date | Value |
|---|---|
| April 04, 2024 | 2.470M |
| April 03, 2024 | 4.171M |
| April 02, 2024 | 4.384M |
| April 01, 2024 | 6.138M |
| March 28, 2024 | 5.607M |
| March 27, 2024 | 5.228M |
| March 26, 2024 | 4.597M |
| March 25, 2024 | 1.354M |
| March 22, 2024 | -0.5597M |
| March 21, 2024 | -0.1876M |
| March 20, 2024 | 0.4503M |
| March 19, 2024 | 0.6098M |
| March 18, 2024 | 1.832M |
| March 15, 2024 | 2.417M |
| March 14, 2024 | 2.896M |
| March 13, 2024 | 3.427M |
| March 12, 2024 | -0.985M |
| March 11, 2024 | -2.846M |
| March 08, 2024 | -2.846M |
| March 07, 2024 | -2.739M |
| March 06, 2024 | -3.005M |
| March 05, 2024 | -2.686M |
| March 04, 2024 | -2.633M |
| March 01, 2024 | -1.676M |
| February 29, 2024 | -1.782M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-11.30M
Minimum
Oct 30 2023
171.08M
Maximum
Feb 10 2021
38.92M
Average
33.37M
Median
Jun 02 2020
Enterprise Value Benchmarks
| Alpine Immune Sciences Inc | 3.924B |
| Eliem Therapeutics Inc | 142.12M |
| NovaBay Pharmaceuticals Inc | 2.645M |
| Palatin Technologies Inc | 28.44M |
| iBio Inc | 16.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.282M |
| Revenue (Quarterly) | 0.2162M |
| Total Expenses (Quarterly) | 2.810M |
| EPS Diluted (Quarterly) | -0.42 |
| Profit Margin (Quarterly) | -1.06K% |
| Earnings Yield | -57.01% |
| Normalized Earnings Yield | -57.68 |